ProCE Banner Activity

ExpressPoints:
Breakthrough Therapeutics for CLL and Other B-Cell Malignancies: Focus on BTK Inhibitors From Development to Clinical Integration

Slideset Download
Download this short summary slideset of key takeaways from a live symposium on BTK inhibitors in CLL and MCL.

Released: December 16, 2022

Expiration: December 15, 2023

No longer available for credit.

Share

Faculty

Jeff DONOTUSESharman

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Ian W. Flinn

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Susan M. O Brien

Susan M. O Brien, MD

Professor of Medicine
Department of Leukemia
University of Texas M.D. Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

BeiGene, Ltd.

Lilly

Program Director Disclosure

Program Director

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Faculty Disclosure

Primary Author

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Susan M. O Brien, MD

Professor of Medicine
Department of Leukemia
University of Texas M.D. Anderson Cancer Center
Houston, Texas